

Microbot Medical Inc.  
Form 8-K  
April 16, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 10, 2018**

**MICROBOT MEDICAL INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b>	<b>000-19871</b>	<b>94-3078125</b>
<b>(State or other jurisdiction of incorporation)</b>	<b>(Commission File Number)</b>	<b>(IRS Employer Identification No.)</b>

**25 Recreation Park Drive, Unit 108**

**Hingham, Massachusetts 02043**

**(Address of Principal Executive Offices) (Zip Code)**

**Registrant's telephone number, including area code: (781) 875-3605**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events.**

On April 10, 2018, Microbot Medical Ltd. (“Microbot Ltd.”), an Israeli corporation and wholly-owned subsidiary of Microbot Medical Inc. (the “Registrant”), delivered an Exercise Notice to CardioSert Ltd. (“CardioSert”), notifying CardioSert of Microbot Ltd.’s election to exercise the option to acquire certain patent-protected technology owned by CardioSert (the “Transferred IP”). With the closing of the acquisition expected late April 2018, CardioSert’s issued U.S. patent and three patent applications pending worldwide will be added to Microbot Ltd.’s patent portfolio which will then have a patent portfolio of 25 issued/allowed patents and 15 patent applications pending worldwide.

On April 16, 2018, the Registrant issued a press release announcing the exercise of the CardioSert option. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

*(d) Exhibits*

<b>Exhibit Number</b>	<b>Description</b>
99.1	<u>Press release, dated April 16, 2018</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**MICROBOT MEDICAL INC.**

By: */s/ Harel Gadot*

Name: Harel Gadot

Title: Chief Executive Officer, President and Chairman

Date: April 16, 2018

